Petrelintide is an investigational once-weekly long-acting amylin analog being developed for obesity and metabolic indications. It is being advanced as both monotherapy and in fixed-dose combinations with incretin-based agents. Current development remains at Phase 2-level programs with no approved marketing status.
A Cleveland Clinic study of nearly 8,000 patients found minimal weight regain one year after stopping semaglutide or tirzepatide, contrasting with clinical trial results. Meanwhile, Eli Lilly's retatrutide and Roche's petrelintide continue development as next-generation obesity treatments.
Zealand Pharma's petrelintide achieved up to 10.7% average weight loss after 42 weeks in a 493-patient phase 2 trial, with placebo-like tolerability but lower efficacy than competing amylin drugs, causing Zealand shares to drop 34%.
Genentech announced positive Phase II results for petrelintide, showing up to 10.7% mean weight loss versus 1.7% placebo at week 42 in people with overweight and obesity, with placebo-like tolerability.
Genentech announced positive Phase II results for CT-388, a dual GLP-1/GIP receptor agonist, showing 22.5% placebo-adjusted weight loss at 48 weeks in people with obesity. The treatment was well-tolerated with low discontinuation rates.
Roche announced positive phase II results for obesity drug petrelintide showing 10.7% weight reduction, while the FDA set a December 18 decision date for breast cancer drug giredestrant.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07589686 |
A Dose-Finding Study of Petrelintide With Enicepatide (RO7795068) in Adults With Obesity or Overweight |
NOT_YET_RECRUITING | PHASE2 |
| NCT07338214 |
Investigating the Pharmacokinetics of Petrelintide Using Different Drug Product Concentrations |
COMPLETED | PHASE1 |
| NCT07076030 |
Pharmacokinetics of Petrelintide Following Administration to Participants With Impaired Renal Function |
COMPLETED | PHASE1 |
| NCT06926842 |
Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 Diabetes (ZUPREME 2) |
ACTIVE_NOT_RECRUITING | PHASE2 |
| NCT06662539 |
Once-weekly Petrelintide Versus Placebo for Obesity or Overweight With Co-morbidities |
COMPLETED | PHASE2 |
